May 31, 2017
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on May 30 recommended approval for Eli Lilly Japan’s rheumatoid arthritis (RA) drug baricitinib, which was approved in Europe earlier this year but rejected in the US...read more